ClinicalTrials.govpublic full text
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
breast cancer, metastatic breast cancer, second-line therapy, triple negative, her-2 negative, hormone receptor negative, abraxane, bevacizumab, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 885276
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.